PHOENIXArizona. , March 2, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, of Urology, Neurology and Orthopedics, today announced the appointment of Sahil Nock as Chief Commercial Officer of the Company, from February 28, 2022.
Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing and business development. He most recently served as US Commercial Marketing Manager at Mentor, the world leader in breast aesthetics and a Johnson & Johnson medical device company. In this role, he was responsible for growing Mentor’s market-leading position in both augmentation and reconstruction. Prior to Mentor, he led market development at Intrexon Corporation, overseeing over $250 million in transactions in a range of industries from healthcare to agriculture. Previously at Abbott, he led one of the most successful medical device launches in history with the introduction of the FreeStyle Libre Diabetes Continuous Glucose Monitor System. Early in his career, Mr. Nock held leadership positions at Danaher and Thermo Fisher Scientific.
Timothy WarbingtonChairman and CEO of the company, said, “I am delighted to welcome Sahil to work alongside our leadership team as we continue to build a world-class organization. Our ability to recruit top talent is key to achieving our short and long term goals. Given Sahil’s proven track record with some of the largest and most recognized brands in healthcare, and his extensive marketing experience to healthcare professionals and consumers, I am confident he will have a immediate impact in accelerating our breakthrough autologous programs including CaverStem®, FemCelz® and StemSpine®.”
Mr. Nock added, “I was drawn to the world-class leadership and disruptive technology platforms of Creative Medical Technology. I look forward to working closely with the team to advance the company’s regenerative medicine programs, which have the potential to revolutionize healthcare.
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company specializing in stem cell technology in the areas of urology, neurology and orthopedics and trades on the Nasdaq under the symbol CELZ. For more information about the company, please visit www.creativemedicaltechnology.com.
This press release may contain forward-looking statements, including, but not limited to, comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements relate to future events and conditions and, therefore, involve risks and uncertainties. Actual results may differ materially from those currently anticipated in these statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
SOURCE Creative Medical Technology Holdings, Inc.